Ed Harlow

Ed Harlow
Institutions Harvard Medical School
Known for Retinoblastoma protein

Ed Harlow (born 1952) is an American molecular biologist.

Harlow received the Ph.D. degree from the Imperial Cancer Research Fund.

Harlow is professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

He has been associate director of the Dana-Farber Cancer Institute as well as research director of the Massachusetts General Hospital Cancer Center and the National Cancer Institute.

From 2009-2011 he was Chief Scientific Officer at Constellation Pharmaceuticals.

Among Harlow's discoveries was the demonstration that the retinoblastoma protein interacts with viral transforming proteins, thereby linking tumor viruses with the cell cycle. He is also the author, with David Lane, of "Using antibodies: a laboratory manual." (1999).[1]

Dr. Harlow has trained scientists in the field of molecular biology and oncology, including Nicholas Dyson (Professor at Harvard Medical School and Scientific Director of the Massachusetts General Hospital Cancer Center), Jacqueline Lees (Professor of Biology at MIT and Associate Director of the Koch Institute), Joshua LaBaer (Virginia G. Piper Chair in Personalized Medicine at Arizona State University and Director of the Biodesign Institute), Matthew Meyerson (Professor of Pathology at the Dana-Farber Cancer Institute and Harvard Medical School and Senior Associate Member of the Broad Institute), Li-Huei Tsai (Picower Professor of Neuroscience at MIT and Director of the Picower Center for Learning and Memory), and Marc Vidal (Director of the Center for Cancer Systems Biology at the Dana-Farber Cancer Institute).

Publications

Awards

References

  1. Harlow, E (1998). Using antibodies: a laboratory manual. ISBN 0879695447.
  2. Dyson, N (1989). "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.". Science. 243: 934–7. doi:10.1126/science.2537532. PMID 2537532.
  3. Whyte, P (1988). "Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product.". Nature. 334: 124–9. doi:10.1038/334124a0. PMID 2968522.
  4. LaBaer, J (1997). "New functional activities for the p21 family of CDK inhibitors.". Genes Dev. 11: 847–62. doi:10.1101/gad.11.7.847. PMID 9106657.
  5. Buchkovich, K (1989). "The retinoblastoma protein is phosphorylated during specific phases of the cell cycle.". Cell. 58: 1097–105. doi:10.1016/0092-8674(89)90508-4. PMID 2673543.
  6. van den Heuvel, S (1993). "Distinct roles for cyclin-dependent kinases in cell cycle control.". Science. 262: 2050–4. doi:10.1126/science.8266103. PMID 8266103.
  7. Harlow, E (1981). "Monoclonal antibodies specific for simian virus 40 tumor antigens.". J Virol. 39: 861–9. PMC 171319Freely accessible. PMID 6169844.
  8. Tsai, L (1994). "p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5.". Nature. 371: 419–23. doi:10.1038/371419a0. PMID 8090221.
  9. Meyerson, M (1992). "A family of human cdc2-related protein kinases.". EMBO J. 11: 2909–17. PMC 556772Freely accessible. PMID 1639063.
  10. Whyte, P (1989). "Cellular targets for transformation by the adenovirus E1A proteins.". Cell. 56: 67–75. doi:10.1016/0092-8674(89)90984-7. PMID 2521301.
This article is issued from Wikipedia - version of the 10/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.